Please use this identifier to cite or link to this item:
|Title:||The Response of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Cell Lines on Standard Therapy and Treatment with an Experimental Alpha-Particle Emitter Immunoconjugate Targeting EGFR (Bi-213- Cetuximab)|
|Authors:||SIEGL MICHAEL; SEIDL C.; PIONTEK GUIDO; WEBER WOLFGANG; BRUCHERTSEIFER FRANK; MORGENSTERN ALFRED; MULTHOFF GABRIELE; PICKHARD ANJA|
|Citation:||JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES vol. 50 no. 1 p. S27|
|Type:||Articles in periodicals and books|
|Abstract:||Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Despite considerable improvements in surgery, radio- and chemotherapy over the last decades, the five-year overall survival has not changed significantly. Radio resistance is a frequent issue that impedes success in therapy. Tumor hypoxia often is causing this resistance, hence targeted therapy with oxygenation-independent alpha-emitters could be an effective strategy for therapy of HNSCC. Another emerging factor for treatment response is infection with human papillomavirus (HPV). HPV associated HNSCC is known to have a better prognosis and therefore is described as distinct entity within HNSCC. Still there are contrary experimental studies on response to therapy and the underlying molecular mechanisms.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.